Incyte Corporation (NASDAQ:INCY) Q4 2022 Earnings Call Transcript

Matt Phipps : Barry, you cited additional competition in MF this year is a reason for the appropriateness of your guidance today. But I guess, I don’t really expect those labels to directly compete with Jakafi. So I wonder if you’re starting to see maybe patients who were kind of suboptimal responders switching a little earlier or now having another option to switch off of Jakafi than they would have prior. If that is kind of the impact you’re talking about?

Barry Flannelly : Sure, Matt. Yes. No, so we don’t really know necessarily, but we do think that the two drugs that are available currently fedratinib and pacritinib are used in the second-line setting almost exclusively. If there’s any use in the first-line setting, it’s hard for us to determine that. In terms of future, obviously, we’re looking to — momelotinib has a PDUFA date in June, and we don’t know what GSK is necessarily going to do with that product. We don’t know what the indication necessarily is. But we think that patients will benefit — continue to benefit from Jakafi because of the differentiation of overall survival, unsurpassed symptom improvement and spleen volume reduction. We think that will continue, and these other drugs will be used in the second-line setting. But we’re not sure exactly how this is going to play out, and that’s why I think we gave the guidance that we did.

Operator: Thank you. We’ve reached the end of our question-and-answer session. I’d like to turn the floor back over for any further or closing comments.

Christine Chiou : Thank you all for participating in the call today and for your questions. The IR team will be available for the rest of the day for follow-up. Thank you, and goodbye.

Operator: Thank you. That does conclude today’s teleconference and webcast. You may disconnect your lines at this time, and have a wonderful day. We thank you for your participation today.